Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)

BACKGROUND: To establish the role of antiemetic therapy with neurokinin-1 (NK(1)) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.) fosaprepitant for the prevention of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstein, C., Jordan, K., Green, S. A., Camacho, E., Khanani, S., Beckford-Brathwaite, E., Vallejos, W., Liang, L. W., Noga, S. J., Rapoport, B. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684151/
https://www.ncbi.nlm.nih.gov/pubmed/26449391
http://dx.doi.org/10.1093/annonc/mdv482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684151/
https://www.ncbi.nlm.nih.gov/pubmed/26449391
http://dx.doi.org/10.1093/annonc/mdv482

Ejemplares similares